MindMed Advances 18-MC, Potential Treatment for Opioid Addiction, Into Further Clinical Testing

Posted by:

MindMed Advances 18-MC, Potential Treatment for Opioid Addiction, Into Further Clinical Testing

[ad_1]

18-MC is a proprietary, non-hallucinogenic molecule, based on the psychedelic ibogaine. In extensive nonclinical testing, 18-MC has shown promise …

[ad_2]

Source link

0

Menu

Blog

Disclaimer

The information on this website is offered for informational use only. MYEBOGA specifically cautions against the use of iboga related products (i) in violation of the law, (ii) without appropriate professional guidance and monitoring, or (iii) without careful personal evaluation of potential risks and hazards. MYEBOGA specifically disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this website. This website does not promote ibogaine services in the R. O. Ireland.

About

This site is 100% voluntary and does not receive any form of payment from any of the providers listed here. In addition, this site does not engage in any way with the supply or manufacture of ibogaine or iboga related products or services. Information is offered for interest only and grew our of a desire to offer a service providing balanced information without any motive for profit.
UA-77446339-1